Tissue engineered human heart valves

Author(s):
gholamreza OMRANIgholamreza OMRANI1,*
1Iran
*Corresponding Author: Corresponding author: gholamreza OMRANI, Iran Email: [email protected]

Multidisciplinary Cardiovascular Annals:Vol. 3, issue 5; e8758
Published online:Apr 21, 2010
Article type:Correction
Received:Sep 14, 2016
Accepted:Apr 14, 2010
How to Cite:OMRANI G. Tissue engineered human heart valves. Multidiscip Cardio Annal. 2010;3(5):e8758. doi:

Abstract

The is no ideal heart valve substitute,
both mechanical and biologic heart
valve have significant limitation in term
of durability, growth potential (for infant
and children), compatibility, resistance
to infection(1).
Tissue-engineered heart valve have been
proposed by physicians and scientists
alike to be the ultimate solution for
treating valvular heart disease rather than
replacing a diseased or defective native
valve with a mechanical or bioprosthesis,
a tissue engineered valve would be a living
organ with the capability for growth,
repair and remodeling in the same way
that the native heart valve does.
Over the last decade attempts to create
tissue engineered heart valve have been
made with varying degrees of success,
constructing these valve from a Varity of
cell types and scaffolding materials. Early
results in animals and limited clinical
application are promising although it
will take many years to demonstrate that
long-term performance of this valve is
comparable or better than conventional
prosthetic heart valve.

Fulltext

Full Text Available is PDF

References

  • 1.
    Full Text Available is PDF.

Copyright

© 2010, Multidisciplinary Cardiovascular Annals. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

31
Oct
2021

Review Insights In Cardiac Tissue Engineering: Cells, Scaffolds, and Pharmacological Agents

Safieh Boroumand,
Azadeh Haeri,
Niloofar Nazeri,
Shahram Rabbani

Boroumand S, Haeri A, Nazeri N, Rabbani S. Review Insights In Cardiac Tissue Engineering: Cells, Scaffolds, and Pharmacological Agents. Iran J Pharm Res. 2021;20(4):e124277. doi: https://doi.org/10.22037/ijpr.2021.114730.15012

21
Feb
2013

Midterm Outcome of Bioprosthetic Valve Replacement in North West of Iran

ramin Baghaei

Baghaei R. Midterm Outcome of Bioprosthetic Valve Replacement in North West of Iran. Multidiscip Cardio Annal. 2013;5(1):e8780. doi:

21
Feb
2007

Surgical Management of Small Aortic Root

Alireza Alizadeh Ghavidel

Alizadeh Ghavidel A. Surgical Management of Small Aortic Root. Multidiscip Cardio Annal. 2007;1(3):e8681. doi:

14
Aug
2012

Redo -tricuspid valve replacement, technical consideration; valve in valve insertion

gholamreza OMRANI

OMRANI G. Redo -tricuspid valve replacement, technical consideration; valve in valve insertion. Multidiscip Cardio Annal. 2012;4(2 & 3):e8776. doi:

11
Sep
2016

Pulmonary Valve Replacement in Patients With Congenital Heart Disease: Is There Any Place for Mechanical Valves?

B. Askari,
M. Sharifi

Askari B, Sharifi M. Pulmonary Valve Replacement in Patients With Congenital Heart Disease: Is There Any Place for Mechanical Valves?. Multidiscip Cardio Annal. 2011;3(2):e8743. doi:

Download PDF2.15 MB
Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCCÂ